Summarising the status of prostate PARPi situation. Today we add FDA approval for abiraterone plus olaparib in BRCA1/2+ 1st line mCRPC patients. We have yet to see what happens with talazoparib plus enzalutamide.

Breaking news👉@FDAoncology approves the combo of abiraterone+Olaparib for mCRPC #prostatecancer with BRCA1 & BRCA2 mutations. Weblink: tinyurl.com/y5v45bda @ONCOALERT Prostate Cancer Foundation UroToday.com Toni Choueiri, MD ZERO Prostate Cancer CancerDotNet #ASCO23 ASCO

Simon C Christopher Sweeney, MBBS Sabine D. Brookman-May Daniel E Spratt Eleni Efstathiou Joaquin Mateo Adam Sharp Arun Azad Neeraj Agarwal, MD, FASCO As I see it, clear benefit for BRCA and less for HRRm. Some non-HRRm may also benefit from ARPi+PARPi, but who are those? Toxicity is a concern as there are some pts that will do as well just on ARPi and we are unable to identify non-HRRm benefiting from the combo.

bilimsel düşünce 🍔 aerometre ☃️ parpi #Ankara

Simon C Neeraj Agarwal, MD, FASCO Adam Sharp Eleni Efstathiou Agreed. With the current data, BRCA pts are clearly the ones to benefit the most from PARPi, alone or combined with ARPi.

Message | رِسَالة يارب العالمين اللهم أجبر ما في خاطري وأستجب لي دعائي انك السميع المجيب 😭🤲🤍

🤣🤣🤣

mands ⁷⁺² 🌙 Louder than bombs

Dai Parpi ormai la figura di 💩 l’hai fatta!!

#oriele

Sowdha Mani Itha parpi

Parpi ets preciosa

Enjoying #SanFrancisco and the scientific feast in #GU23 . Exciting data on #PARPi in mCRPC by Neeraj Agarwal, MD, FASCO and Alan H Bryce Wonder can radiation play a role as well🤔 Daniel E Spratt Amar Kishan Felix Feng Vedang Murthy Sophia Kamran, MD Priyamvada Maitre

#voleinosportv #vnl
sportv
Vai Brasil! 🇧🇷🇧🇷🇧🇷🇧🇷

Elena Castro Simon C Christopher Sweeney, MBBS Daniel E Spratt Eleni Efstathiou Joaquin Mateo Adam Sharp Arun Azad Neeraj Agarwal, MD, FASCO I think it is responsibility of researchers + pharma involved in #PARPi studies to now evaluate the non- #HRRm pts in detail (incl. additional biomarker analysis) and identify who in this group benefits + why and who doesn’t (and in whom additional toxicity is not acceptable)

Gowri Sankar D Parpi puhal palani

Lembro quando vir um vídeo do Jeonghan na fy do tiktok e me apaixonei pelo sorriso dele.
Fui ver quem era , me aprofundar mais e conheci 13 garotos lindos, de um coração tão grande.
Uma família de 13 membros.

#팀세븐틴_보고올랐지_8주년까지 #SEVENTEEN_To_8finity

Such an honour to speak at the Global Academy of Women's Cancer on the post #PARPi 💊 therapeutic landscape in ovarian cancer
🔝🔝 discussions & debates

Tired of egregious egress? Fed up with unpredictable Big Tech cloud billing practices? Try Vultr instead, offering Optimized Compute from $28/mo. Deploy now with $250 in credit for your first 30 days!

#EASImmuneResponses

Outstanding talks and a great opportunity to discuss our results on the association between PARPi sensitivity and the activation of the STING-IFN pathway in breast cancer Vall d’Hebron Institute of Oncology (VHIO) Violeta Serra Alba Llop Guevara

🙏 EACR AACR SIC Italian Cancer Society

Don’t get caught with your shield down! ⚔️🛡️

Based on community feedback, we’ve added clearer FX animations for Critical Hits and improved guidance on when to Block and Parry.

Sign up for Beta at Playwayfinder.com. Visit the website to see all of the changes!

fê || baby carat ☆⁵ to you

🔥Parpi shows OS benefit in HRD+VE ovary cancer population
🔹 HRD +ve ➡️ definite role of Parpi as maintenance
5y OS 66% vs 48% with Ola + Bev
Aggrego Oncology
Dr Amol Akhade Bijoy Telivala #MedTwitter OncoAlert annalsofoncology.org/article/S0923-…
Annals of Oncology

Àwé Alágbo ™ CAC-OFR Toh fa!

Frontline PARP inhibitor maintenance in BRCA1/2 carriers improves 5-year survival by 20%. Hence, it is important to offer germline genetic testing to all women with ovarian cancer and offer frontline PARPi maintenance in advanced ovarian cancer.

Dr. Lederman at #BRCA symposium